Dianthus Therapeutics (DNTH) Amortization of Deferred Charges (2022 - 2025)

Dianthus Therapeutics' Amortization of Deferred Charges history runs 4 years deep, the most recent figure standing at $72000.0 for Q3 2025.

• On a quarterly basis, Amortization of Deferred Charges fell 20.88% year-over-year to $72000.0 in Q3 2025; TTM through Sep 2025 was $299000.0, a 13.83% decrease from a year earlier, with the FY2024 full-year figure at $316000.0, up 9.72% from the prior year.
• Amortization of Deferred Charges improved to $72000.0 in Q3 2025 per DNTH's latest filing, from $69000.0 in the prior quarter.
• Across five years, Amortization of Deferred Charges topped out at $699000.0 in Q1 2022 and bottomed at $38000.0 in Q4 2022.
• The 4-year median for Amortization of Deferred Charges is $72000.0 (2025), against an average of $122153.8.
• Biggest YoY gain for Amortization of Deferred Charges was 118.42% in 2023; the steepest drop was 90.41% in 2023.
• Year by year, Amortization of Deferred Charges stood at $38000.0 in 2022, then jumped by 118.42% to $83000.0 in 2023, then tumbled by 37.35% to $52000.0 in 2024, then soared by 38.46% to $72000.0 in 2025.
• Per Business Quant, the three latest DNTH Amortization of Deferred Charges figures stand at $72000.0 (Q3 2025), $69000.0 (Q2 2025), and $106000.0 (Q1 2025).